XML 41 R25.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenue (Tables) | 3 Months Ended
--- | ---
Sep. 30, 2020
Revenue from Contract with Customer [Abstract] |
Schedule of Total Revenue by Product and by U.S versus Rest of World | The following table presents detail regarding the composition of our total revenue by product and by U.S. versus rest of world, “RoW”:
| Three months ended September 30,
| 2020 |  | 2019
(In millions) | U.S. |  | RoW |  | Total |  | U.S. |  | RoW |  | Total
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing | $ | 72.1 |  |  | $ | 8.5 |  |  | $ | 80.6 |  |  | $ | 100.6 |  |  | $ | 3.9 |  |  | $ | 104.5 |
Prenatal | 16.4 |  |  | 0.1 |  |  | 16.5 |  |  | 23.5 |  |  | — |  |  | 23.5 |
GeneSight | 11.9 |  | — |  |  | 11.9 |  | 22.7 |  | — |  |  | 22.7
Vectra | 9.1 |  | — |  |  | 9.1 |  | 11.0 |  | — |  |  | 11.0
myChoice CDx | 7.6 |  | 0.2 |  |  | 7.8 |  | 1.3 |  | — |  |  | 1.3
Prolaris | 6.4 |  | — |  |  | 6.4 |  | 6.5 |  | — |  |  | 6.5
EndoPredict | 0.4 |  | 2.4 |  | 2.8 |  | 0.5 |  | 1.8 |  | 2.3
Other | 0.6 |  | — |  |  | 0.6 |  | 0.1 |  | 0.1 |  | 0.2
Total molecular diagnostic revenue | 124.5 |  | 11.2 |  | 135.7 |  | 166.2 |  | 5.8 |  | 172.0
Pharmaceutical and clinical service revenue | 9.5 |  | — |  |  | 9.5 |  | 8.5 |  | 5.9 |  | 14.3
Total revenue | $ | 134.0 |  |  | $ | 11.2 |  |  | $ | 145.2 |  |  | $ | 174.7 |  |  | $ | 11.7 |  |  | $ | 186.3 |
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
| Three months ended September 30,
| 2020 |  | 2019
Deferred revenue - beginning balance | $ | 32.8 |  |  | $ | 2.2 |
Revenue recognized | (2.3) |  |  | (0.4) |
Prepayments | 1.8 |  |  | 0.3 |
Deferred revenue - ending balance | $ | 32.3 |  |  | $ | 2.1 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration